doi: 10.1111/bcpt.13618.
Epub 2021 Jun 23.
Risk of muscle toxicity events for daptomycin with and without statins: Analysis of the Japanese Adverse Event Report database
Affiliations
- PMID: 34117712
- DOI: 10.1111/bcpt.13618
Item in Clipboard
Risk of muscle toxicity events for daptomycin with and without statins: Analysis of the Japanese Adverse Event Report database
Basic Clin Pharmacol Toxicol.
2021 Sep.
Free article
No abstract available
Keywords: creatine phosphokinase; daptomycin; muscle toxicity; rhabdomyolysis; statin.
Similar articles
-
Effect of Statin Coadministration on the Risk of Daptomycin-Associated Myopathy.Clin Infect Dis. 2018 Oct 15;67(9):1356-1363. doi: 10.1093/cid/ciy287. Clin Infect Dis. 2018. PMID: 29668884 Free PMC article.
-
Statins and daptomycin: safety assessment of concurrent use and evaluation of drug interaction liability.Drug Metabol Drug Interact. 2013;28(1):49-58. doi: 10.1515/dmdi-2012-0033. Drug Metabol Drug Interact. 2013. PMID: 23314530
-
Musculoskeletal safety outcomes of patients receiving daptomycin with HMG-CoA reductase inhibitors.Antimicrob Agents Chemother. 2014 Oct;58(10):5726-31. doi: 10.1128/AAC.02910-14. Epub 2014 Jul 14. Antimicrob Agents Chemother. 2014. PMID: 25022580 Free PMC article.
-
Musculoskeletal toxicities in patients receiving concomitant statin and daptomycin therapy.Am J Health Syst Pharm. 2019 Feb 1;76(4):206-210. doi: 10.1093/ajhp/zxy036. Am J Health Syst Pharm. 2019. PMID: 30689699 Review.
-
Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment.Drug Saf. 2010 Mar 1;33(3):171-87. doi: 10.2165/11319380-000000000-00000. Drug Saf. 2010. PMID: 20158283 Review.
Cited by
-
Association Between Statin Use and Daptomycin-related Musculoskeletal Adverse Events: A Mixed Approach Combining a Meta-analysis and a Disproportionality Analysis.Clin Infect Dis. 2022 Oct 12;75(8):1416-1422. doi: 10.1093/cid/ciac128. Clin Infect Dis. 2022. PMID: 35262686 Free PMC article.
-
Pharmacovigilance Strategies to Address Resistance to Antibiotics and Inappropriate Use-A Narrative Review.Antibiotics (Basel). 2024 May 16;13(5):457. doi: 10.3390/antibiotics13050457. Antibiotics (Basel). 2024. PMID: 38786184 Free PMC article. Review.
-
Reporting of Drug-Induced Myopathies Associated with the Combination of Statins and Daptomycin: A Disproportionality Analysis Using the US Food and Drug Administration Adverse Event Reporting System.J Clin Med. 2023 May 18;12(10):3548. doi: 10.3390/jcm12103548. J Clin Med. 2023. PMID: 37240654 Free PMC article.
-
The Effect of Concomitant Usage of Analgesics on Immune Checkpoint Inhibitor-related Interstitial Lung Disease.In Vivo. 2023 May-Jun;37(3):1260-1265. doi: 10.21873/invivo.13203. In Vivo. 2023. PMID: 37103090 Free PMC article.
References
REFERENCES
-
- Niki Y. Practical Guidelines for the Management and Treatment of Infections Caused by MRSA, 2019 Edition. 2019. (Accessed 23 Dec, 2020, at http://www.chemotherapy.or.jp/guideline/guideline_mrsa_2019.pdf.)
-
- Teng C, Baus C, Wilson JP, Frei CR. Rhabdomyolysis associations with antibiotics: a pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS). Int J Med Sci. 2019;16(11):1504-1509.
-
- Dare RK, Tewell C, Harris B, et al. Effect of statin coadministration on the risk of daptomycin-associated myopathy. Clin Infect Dis. 2018;67(9):1356-1363.
-
- Bland CM, Bookstaver PB, Lu ZK, Dunn BL, Rumley KF, Southeastern Research Group E. Musculoskeletal safety outcomes of patients receiving daptomycin with HMG-CoA reductase inhibitors. Antimicrob Agents Chemother. 2014;58(10):5726-5731.
-
- Parra-Ruiz J, Duenas-Gutierrez C, Tomas-Jimenez C, Linares-Palomino JP, Garrido-Gomez J, Hernandez-Quero J. Safety analysis of high dose (>6 mg/kg/day) daptomycin in patients with concomitant statin therapy. Eur J Clin Microbiol Infect Dis. 2012;31(8):1771-1774.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
